A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease

Vaccine

Volumn 32, Issue 28, 2014, Pages 3525-3532

  Serna, Carylinda ^a   Lara, Joshua A ^a   Rodrigues, Silas P ^a,c   Marques, Alexandre F ^a,b   Almeida, Igor C ^a   Maldonado, Rosa A ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Chagas disease; Immunoinformatics; Proteomics; Trypanosoma cruzi; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIBODY; B LYMPHOCYTE ANTIGEN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN ASSOCIATED SURFACE PROTEIN; PEPTIDE; PLACEBO; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; EPITOPE; MEMBRANE PROTEIN; MUCIN; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; PROTOZOON ANTIBODY; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; DRUG CONJUGATION; FEMALE; HEART; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; SURVIVAL RATE; TRYPANOSOMA CRUZI; TRYPOMASTIGOTE; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C3H MOUSE; IMMUNOLOGY; MOLECULAR GENETICS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; CHAGAS DISEASE; CYTOKINES; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, HUMORAL; MEMBRANE GLYCOPROTEINS; MICE, INBRED BALB C; MICE, INBRED C3H; MOLECULAR SEQUENCE DATA; MUCINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TRYPANOSOMA CRUZI; VACCINES, SYNTHETIC;

EID: 84901470253     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.026     Document Type: Article

References (57)

1. Rassi A., Rassi A., Marcondes de Rezende J. American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 2012, 26:275-291.
2. Vazquez-Chagoyan J.C., Gupta S., Garg N.J. Vaccine development against Trypanosoma cruzi and Chagas disease. Adv Parasitol 2011, 75:121-146.
3. Lee B.Y., Bacon K.M., Wateska A.R., Bottazzi M.E., Dumonteil E., Hotez P.J. Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vacc Immunother 2012, 8:1293-1301.
4. Acosta-Serrano A., Hutchinson C., Nakayasu E.S., Almeida I.C., Carrington M. Comparison and evolution of the surface architecture of trypanosomatid parasites. Trypanosomes: after the genome 2007, 319-337. Horizon Scientific Press, Norwich, UK. J.D. Barry, J.C. Mottram, R. McCulloch, A. Acosta-Serrano (Eds.).
5. El-Sayed N.M., Myler P.J., Bartholomeu D.C., Nilsson D., Aggarwal G., Tran A.N., et al. The genome sequence of Trypanosoma cruzi, etiologic agent of Chagas disease. Science 2005, 309:409-415.
6. De Pablos L.M., Osuna A. Multigene families in Trypanosoma cruzi and their role in infectivity. Infect Immun 2012, 80:2258-2264.
7. Nakayasu E.S., Sobreira T.J., Torres R., Ganiko L., Oliveira P.S., Marques A.F., et al. Improved proteomic approach for the discovery of potential vaccine targets in Trypanosoma cruzi. J Proteome Res 2012, 11:237-246.
8. Andrews N.W., Colli W. Adhesion and interiorization of Trypanosoma cruzi in mammalian cells. J Protozool 1982, 29:264-269.
9. Bayer-Santos E., Aguilar-Bonavides C., Rodrigues S.P., Cordero E.M., Marques A.F., Varela-Ramirez A., et al. Proteomic analysis of Trypanosoma cruzi secretome: characterization of two populations of extracellular vesicles and soluble proteins. J Proteome Res 2013, 12:883-897.
10. Marques A.F., Nakayasu E.S., Almeida I.C. Purification of extracellular and intracellular amastigotes of Trypanosoma cruzi from mammalian host-infected cells. Protoc Exchange 2011, http://www.nature.com/protocolexchange/protocols/22402011.
11. Singh H., Raghava G.P. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics 2003, 19:1009-1014.
12. Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo 1962, 4:389-396.
13. Almeida I.C., Covas D.T., Soussumi L.M., Travassos L.R. A highly sensitive and specific chemiluminescent enzyme-linked immunosorbent assay for diagnosis of active Trypanosoma cruzi infection. Transfusion (Paris) 1997, 37:850-857.
14. Pinazo M.J., Munoz J., Posada E., Lopez-Chejade P., Gallego M., Ayala E., et al. Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 2010, 54:4896-4899.
15. Almeida I.C.M.S., Gorin P.A., Travassos L.R. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol 1991, 146:2394-2400.
16. Cummings K.L., Tarleton R.L. Rapid quantitation of Trypanosoma cruzi in host tissue by real-time PCR. Mol Biochem Parasitol 2003, 129:53-59.
17. Vasconcelos J.R., Hiyane M.I., Marinho C.R., Claser C., Machado A.M., Gazzinelli R.T., et al. Protective immunity against Trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 2004, 15:878-886.
18. Krettli A.U. The utility of anti-trypomastigote lytic antibodies for determining cure of Trypanosoma cruzi infections in treated patients: an overview and perspectives. Mem Inst Oswaldo Cruz 2009, 104(Suppl. 1):142-151.
19. Almeida I.C., Ferguson M.A., Schenkman S., Travassos L.R. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J 1994, 304(Pt 3):793-802.
20. Almeida I.C., Milani S.R., Gorin P.A., Travassos L.R. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol 1991, 146:2394-2400.
21. Pereira-Chioccola V.L., Acosta-Serrano A., Correia de Almeida I., Ferguson M.A., Souto-Padron T., Rodrigues M.M., et al. Mucin-like molecules form a negatively charged coat that protects Trypanosoma cruzi trypomastigotes from killing by human anti-alpha-galactosyl antibodies. J Cell Sci 2000, 113(Pt 7):1299-1307.
22. Abrahamsohn I.A., da Silva A.P., Coffman R.L. Effects of interleukin-4 deprivation and treatment on resistance to Trypanosoma cruzi. Infect Immun 2000, 68:1975-1979.
23. Michailowsky V., Silva N.M., Rocha C.D., Vieira L.Q., Lannes-Vieira J., Gazzinelli R.T. Pivotal role of interleukin-12 and interferon-gamma axis in controlling tissue parasitism and inflammation in the heart and central nervous system during Trypanosoma cruzi infection. Am J Pathol 2001, 159:1723-1733.
24. Hunter C.A., Ellis-Neyes L.A., Slifer T., Kanaly S., Grunig G., Fort M., et al. IL-10 is required to prevent immune hyperactivity during infection with Trypanosoma cruzi. J Immunol 1997, 158:3311-3316.
25. Aliberti J.C., Cardoso M.A., Martins G.A., Gazzinelli R.T., Vieira L.Q., Silva J.S. Interleukin-12 mediates resistance to Trypanosoma cruzi in mice and is produced by murine macrophages in response to live trypomastigotes. Infect Immun 1996, 64:1961-1967.
26. Tosello Boari J., Amezcua Vesely M.C., Bermejo D.A., Ramello M.C., Montes C.L., Cejas H., et al. IL-17RA signaling reduces inflammation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS Pathog 2012, 8:e1002658.
27. Magalhaes L.M., Villani F.N., Nunes Mdo C., Gollob K.J., Rocha M.O., Dutra W.O. High interleukin 17 expression is correlated with better cardiac function in human Chagas disease. J Infect Dis 2013, 207:661-665.
28. Abrahamsohn I.A., Coffman R.L. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol 1996, 84:231-244.
29. Arruda L.B., Sim D., Chikhlikar P.R., Maciel M., Akasaki K., August J.T., et al. Dendritic cell-lysosomal-associated membrane protein (LAMP) and LAMP-1-HIV-1 gag chimeras have distinct cellular trafficking pathways and prime T and B cell responses to a diverse repertoire of epitopes. J Immunol 2006, 177:2265-2275.
30. Singh B., Lee K.C., Fraga E., Wilkinson A., Wong M., Barton M.A. Minimum peptide sequences necessary for priming and triggering of humoral and cell-mediated immune responses in mice: use of synthetic peptide antigens of defined structure. J Immunol 1980, 124:1336-1343.
31. da Silva A.N., Nascimento E.J., Cordeiro M.T., Gil L.H., Abath F.G., Montenegro S.M., et al. Identification of continuous human B-cell epitopes in the envelope glycoprotein of dengue virus type 3 (DENV-3). PLoS ONE 2009, 4:e7425.
32. Reynolds J., Haxby J., Juggapah J.K., Evans D.J., Pusey C.D. Identification of a nephritogenic immunodominant B and T cell epitope in experimental autoimmune glomerulonephritis. Clin Exp Immunol 2009, 155:311-319.
33. Avalos A.M., Ploegh H.L. Early BCR events and antigen capture, processing, and loading on MHC class II on B cells. Front Immunol 2014, 5:92.
34. Schuette V., Burgdorf S. The ins-and-outs of endosomal antigens for cross-presentation. Curr Opin Immunol 2014, 26C:63-68.
35. Baker K., Rath T., Lencer W.I., Fiebiger E., Blumberg R.S. Cross-presentation of IgG-containing immune complexes. Cell Mol Life Sci: CMLS 2013, 70:1319-1334.
36. De Pablos L.M., Gonzalez G.G., Solano Parada J., Seco Hidalgo V., Diaz Lozano I.M., Gomez Samblas M.M., et al. Differential expression and characterization of a member of the mucin-associated surface protein family secreted by Trypanosoma cruzi. Infect Immun 2011, 79:3993-4001.
37. Bartholomeu D.C., Cerqueira G.C., Leao A.C., daRocha W.D., Pais F.S., Macedo C., et al. Genomic organization and expression profile of the mucin-associated surface protein (masp) family of the human pathogen Trypanosoma cruzi. Nucleic Acids Res 2009, 37:3407-3417.
38. Atwood J.A., Minning T., Ludolf F., Nuccio A., Weatherly D.B., Alvarez-Manilla G., et al. Glycoproteomics of Trypanosoma cruzi trypomastigotes using subcellular fractionation, lectin affinity, and stable isotope labeling. J Proteome Res 2006, 5:3376-3384.
39. Atwood J.A., Weatherly D.B., Minning T.A., Bundy B., Cavola C., Opperdoes F.R., et al. The Trypanosoma cruzi proteome. Science 2005, 309:473-476.
40. Murta S.M., Nogueira F.B., Dos Santos P.F., Campos F.M., Volpe C., Liarte D.B., et al. Differential gene expression in Trypanosoma cruzi populations susceptible and resistant to benznidazole. Acta Trop 2008, 107:59-65.
41. Krettli A.U., Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infections. J Immunol 1976, 116:755-760.
42. Gazzinelli R.T., Pereira M.E., Romanha A., Gazzinelli G., Brener Z. Direct lysis of Trypanosoma cruzi: a novel effector mechanism of protection mediated by human anti-gal antibodies. Parasite Immunol 1991, 13:345-356.
43. Kierszenbaum F. Protection of congenitally athymic mice against Trypanosoma cruzi infection by passive antibody transfer. J Parasitol 1980, 66:673-675.
44. Boscardin S.B., Torrecilhas A.C., Manarin R., Revelli S., Rey E.G., Tonelli R.R., et al. Chagas' disease: an update on immune mechanisms and therapeutic strategies. J Cell Mol Med 2010, 14:1373-1384.
45. Wurster A.L., Rodgers V.L., White M.F., Rothstein T.L., Grusby M.J. Interleukin-4-mediated protection of primary B cells from apoptosis through Stat6-dependent up-regulation of Bcl-xL. J Biol Chem 2002, 277:27169-27175.
46. Galvao Da Silva A.P., Jacysyn J.F., De Almeida Abrahamsohn I. Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response. Immunology 2003, 108:230-237.
47. Hoft D.F., Schnapp A.R., Eickhoff C.S., Roodman S.T. Involvement of CD4(+) Th1 cells in systemic immunity protective against primary and secondary challenges with Trypanosoma cruzi. Infect Immun 2000, 68:197-204.
48. Boari J.T., Amezcua Vesely M.C., Bemejo D.A., Ramello M.C., Montes C.L., Cejas H., et al. IL-17RA signaling reduces inflamation and mortality during Trypanosoma cruzi infection by recruiting suppressive IL-10-producing neutrophils. PLoS Pathog 2012, 8:e1002658.
49. da Matta Guedes P.M., Gutierrez F.R., Maia F.L., Milanezi C.M., Silva G.K., Pavanelli W.R., et al. IL-17 produced during Trypanosoma cruzi infection plays a central role in regulating parasite-induced myocarditis. PLoS Negl Trop Dis 2010, 4:e604.
50. Miyazaki Y., Hamano S., Wang S., Shimanoe Y., Iwakura Y., Yoshida H. IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection. J Immunol 2010, 185:1150-1157.
51. Rottenberg M.E., Bakhiet M., Olsson T., Kristensson K., Mak T., Wigzell H., et al. Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun 1993, 61:5129-5133.
52. Tarleton R.L., Koller B.H., Latour A., Postan M. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 1992, 356:338-340.
53. Junqueira C., Caetano B., Bartholomeu D.C., Melo M.B., Ropert C., Rodrigues M.M., et al. The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 2010, 12:e29.
54. Cunha-Neto E., Teixeira P.C., Fonseca S.G., Bilate A.M., Kalil J. Myocardial gene and protein expression profiles after autoimmune injury in Chagas' disease cardiomyopathy. Autoimmun Rev 2011, 10:163-165.
55. de Araujo F.F., Vitelli-Avelar D.M., Teixeira-Carvalho A., Antas P.R., Assis Silva Gomes J., Sathler-Avelar R., et al. Regulatory T cells phenotype in different clinical forms of Chagas' disease. PLoS Negl Trop Dis 2011, 5:e992.
56. Morrot A., Barreto de Albuquerque J., Berbert L.R., de Carvalho Pinto C.E., de Meis J., Savino W. Dynamics of lymphocyte populations during Trypanosoma cruzi infection: from thymocyte depletion to differential cell expansion/contraction in peripheral lymphoid organs. J Trop Med 2012, 2012:747185.
57. + lymphocytes in Chagas disease: possible relationship with an immunoendocrine imbalance. Ann NY Acad Sci 2012, 1262:27-36.